Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04104776 · ClinicalTrials.gov registry record · Phase 1

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

A Phase 1 study of Advanced Solid Tumor and Endometrial Cancer, sponsored by Novartis Pharmaceuticals.

Recruiting
Registry status
Phase 1
Development phase
275
Enrollment target
20
Study locations

NCT04104776: Recruiting Phase 1 study of Advanced Solid Tumor and Endometrial Cancer, sponsored by Novartis Pharmaceuticals.

NCT04104776 is a Phase 1 study of Advanced Solid Tumor and Endometrial Cancer that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 275 participants, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (44% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04104776, a Phase 1 study of Advanced Solid Tumor and Endometrial Cancer, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.

RECRUITING
Registry status
Phase 1
Development phase
275 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.

Primary Outcome

The maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of Tulmimetostat as monotherapy in patients with advanced tumors.

Conditions Studied

Advanced Solid Tumor Endometrial Cancer Diffuse Large B Cell Lymphoma Metastatic Castration-Resistant Prostate Cancer Prostatic Neoplasms, Castration-Resistant Lymphoma, T-Cell Mesothelioma, Malignant Ovarian Clear Cell Carcinoma

Interventions

  • DRUG Enzalutamide
  • DRUG Tulmimetostat

Study Locations (20)

New York

  • NYU Langone Medical Center - Laura and Isaac Perlmutter Cancer Center - New York
  • Weill Medical College of Cornell University - New York
  • Montefiore Einstein Center for Cancer Care - The Bronx

Other

  • Bergonie Institute - Bordeaux
  • Oscar Lambret Center - Lille
  • Leon Berard Center - Lyon

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana Farber Cancer Institute - Boston

Michigan

  • University of Michigan Hospital - Ann Arbor
  • South Texas Accelerated Research Therapeutics (Start) - Midwest Location - Grand Rapids

Washington

  • Swedish Cancer Institute - Seattle
  • Fred Hutchinson Cancer - Seattle

Georgia

  • Winship Cancer Institute of Emory University - Atlanta

Illinois

  • University of Chicago Medical Center - Chicago

Maryland

  • University of Maryland - Marlene and Stewart Greenebaum Cancer Center - Baltimore

Trial Details

FieldValue
Enrollment Target 275 participants
Start Date 2019-09-18
Est. Completion 2030-02-27
Phase Phase 1
Novartis Pharmaceuticals

1,375 total trials

What NCT04104776 shows while recruiting

NCT04104776 is an interventional study that assigns participants to a tested intervention. The registered 275 participants enrollment target is mid-sized for trials with a published cap, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (44% higher).

The record links to 8 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Enzalutamide is the first listed.

NCT04104776 names 20 study sites across 13 states, led by New York, Other, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04104776 about?

NCT04104776 is a clinical study titled "A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas". The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.

What is the current status of trial NCT04104776?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 275 participants. The study started on 2019-09-18. Estimated completion is 2030-02-27.

What conditions does trial NCT04104776 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, Endometrial Cancer, Diffuse Large B Cell Lymphoma, Metastatic Castration-Resistant Prostate Cancer, Prostatic Neoplasms, Castration-Resistant.

What interventions are being tested in trial NCT04104776?

The interventions under investigation include: Enzalutamide (DRUG), Tulmimetostat (DRUG).

Who is sponsoring clinical trial NCT04104776?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04104776 being conducted?

This trial has 20 study locations across Georgia, Illinois, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04104776's enrollment target sits among peer trials

275 40th of 189 higher than 150 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01269190 · 275 participants · NA

    Wide-Field and High Resolution In Vivo Imaging in Visualizing Lesions in Patients With Oral Neoplasia Undergoing Surgery

  • NCT01900132 · 275 participants · NA

    Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteers

  • NCT04765150 · 275 participants

    Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification

  • NCT04960579 · 275 participants · Phase 1

    P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT04104776

Source: ClinicalTrials.gov NCT04104776, the US trial registry maintained by the National Library of Medicine. NCT04104776 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.